Article Text

Download PDFPDF
Anti-tumour necrosis factor α treatment in chronic recurrent inflammation of the anterior segment of the eye in patients resistant to standard immunomodulatory treatment
  1. Y El-Shabrawi1,
  2. H Mangge2,
  3. J Hermann3
  1. 1Department of Ophthalmology, Karl-Franzens University, Graz, Austria
  2. 2Department of Laboratory Medicine and Paediatric Immunology/Rheumatology, Karl-Franzens University, Graz, Austria
  3. 3Department of Internal Medicine, Karl-Franzens University, Graz, Austria
  1. Correspondence to:
    Dr Y El-Shabrawi
    Department of Ophthalmology, Karl Franzens University Hospital, Auenbruggerplatz 4, 8036 Graz, Austria;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Recurrent or chronic anterior uveitis leads to a drop of vision below 20/50 in 23% of patients; 11% will eventually be legally blind.1,2 Thus the treatment of these patients still presents a challenge, and additional treatments are needed. In a previous study we found that anti-tumour necrosis factor α (anti-TNFα) treatment was highly efficient in a patient with an acute HLA-B27 associated uveitis.3 Thus we tested the efficacy of anti-TNFα treatment, consisting of a combined immunomodulatory drug and corticosteroids, in chronic inflammatory diseases of the anterior segment of the eye, non-responsive to standard anti-inflammatory treatment.


Nine patients with uveitis with associated systemic disease were included (table 1). Eight of these patients had a rheumatic disease (five had a spondyloarthropathy (all were HLA-B27 positive), two had juvenile idiopathic arthritis (JIA; one Still’s disease, …

View Full Text